Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02303821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02303821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2015
Completion date
June 28, 2024
Enrollment
141 (actual)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all)